Phathom Pharmaceuticals, Inc.
PHAT
$9.82
-$0.18-1.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 67.80% | 71.59% | 64.98% | 17.10% | -13.84% |
| Total Depreciation and Amortization | -37.85% | -33.68% | -18.32% | -12.69% | -17.29% |
| Total Amortization of Deferred Charges | 21.26% | 28.62% | 31.58% | 46.80% | 46.84% |
| Total Other Non-Cash Items | -29.86% | -41.88% | -16.91% | -12.24% | -13.58% |
| Change in Net Operating Assets | 117.33% | 144.78% | -212.42% | -850.64% | -26.96% |
| Cash from Operations | 81.58% | 92.12% | 77.80% | 11.30% | -23.05% |
| Capital Expenditure | -238.89% | -1,640.00% | 38.64% | -110.87% | 55.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -238.89% | -1,640.00% | 38.64% | -110.87% | 55.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -2.39% | -99.76% | 280.95% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.37% | -100.22% | -99.68% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 159.96% | 86.14% | -124.66% | -36.42% | -43.59% |